Home › Compare › GRCL vs XYLD

GRCL vs XYLD: Dividend Comparison 2026

GRCL yields 19.51% · XYLD yields 11.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRCL wins by $45.0K in total portfolio value
10 years
GRCL
GRCL
● Live price
19.51%
Share price
$10.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$70.9K
Annual income
$6,394.90
Full GRCL calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
11.20%
Share price
$38.36
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.9K
Annual income
$3,351.03
Full XYLD calculator →

Portfolio growth — GRCL vs XYLD

📍 GRCL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRCLXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRCL + XYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
GRCL pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRCL
Annual income on $10K today (after 15% tax)
$1,658.54/yr
After 10yr DRIP, annual income (after tax)
$5,435.67/yr
XYLD
Annual income on $10K today (after 15% tax)
$952.37/yr
After 10yr DRIP, annual income (after tax)
$2,848.38/yr
At 15% tax rate, GRCL beats the other by $2,587.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRCL + XYLD for your $10,000?

GRCL: 50%XYLD: 50%
100% XYLD50/50100% GRCL
Portfolio after 10yr
$48.4K
Annual income
$4,872.96/yr
Blended yield
10.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GRCL right now

GRCL
Analyst Ratings
3
Buy
5
Hold
Consensus: Hold
Price Target
$6.00
-41.5% upside vs current
Range: $6.00 — $6.00
Altman Z
1.5
Piotroski
3/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRCL buys
0
XYLD buys
0
No recent congressional trades found for GRCL or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRCLXYLD
Forward yield19.51% ✓11.20%
Annual dividend / share$2.00$4.30 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$70.9K ✓$25.9K
Annual income after 10y$6,394.90 ✓$3,351.03
Total dividends collected$39.8K ✓$20.2K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: GRCL vs XYLD ($10,000, DRIP)

YearGRCL PortfolioGRCL Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$12,651$1,951.22$10,840$1,120.44+$1.8K → GRCL
2$15,844$2,307.04$11,786$1,249.59+$4.1K → GRCL
3$19,653$2,700.22$12,854$1,397.78+$6.8K → GRCL
4$24,159$3,130.30$14,063$1,568.33+$10.1K → GRCL
5$29,447$3,596.27$15,434$1,765.19+$14.0K → GRCL
6$35,604$4,096.58$16,995$1,993.14+$18.6K → GRCL
7$42,726$4,629.21$18,777$2,257.95+$23.9K → GRCL
8$50,908$5,191.72$20,818$2,566.58+$30.1K → GRCL
9$60,253$5,781.31$23,163$2,927.50+$37.1K → GRCL
10$70,866$6,394.90$25,865$3,351.03+$45.0K → GRCL

GRCL vs XYLD: Complete Analysis 2026

GRCL — Stock

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

Full GRCL Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this GRCL vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRCL vs SCHDGRCL vs JEPIGRCL vs OGRCL vs KOGRCL vs MAINGRCL vs QYLDGRCL vs JEPQGRCL vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.